幽门螺杆菌致病机制及治疗研究进展

冉 周(蒙古医科大学研究生学院，中国)
佳林 王(内蒙古自治区人民医院消化内科，中国)

摘要

幽门螺杆菌（Helicobacter pylori，H.pylori）的全球流行率估计约为44亿，中国大陆约有5.89亿人感染了Hp。质子泵抑制剂、抗生素与铋剂作为常规疗法，然而在近些年的研究中抗生素的耐药率逐年增高，抗生素的副反应也越来越多，针对这些问题人们提出联合使用益生菌的治疗方案，论文系统综述了Hp致病机制、治疗方案，临床疗效，并对未来研究方向进行展望。

关键词

幽门螺杆菌；致病机制；治疗方法

参考

BRITO B B D, SILVA F A F D, SOARES A S, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection [J]. 2019, 25(37): 5578-89.

REN S, CAI P, LIU Y, et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis [J]. 2022, 37(3): 464-70.

SUGANO K, TACK J, KUIPERS E J, et al. Kyoto global consensus report on Helicobacter pylori gastritis [J]. 2015, 64(9): 1353-67.

GASTROENTEROLOGY D Y G J. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits [J]. 2015, 148(4): 719.

黄翠香,陈曦,包郁,等.幽门螺杆菌与胃肠及胃肠外疾病关系的研究进展[J].重庆医学,2022(51):3029-3333.

KAVITT R T, LIPOWSKA A M, ANYANE-YEBOA A, et al. Diagnosis and Treatment of Peptic Ulcer Disease [J]. 2019, 132(4): 447-56.

ZHONG Y, ANDERL F, KRUSE T, et al. Helicobacter pylori HP0231 Influences Bacterial Virulence and Is Essential for Gastric Colonization [J]. 2016, 11(5): e0154643.

JOURNAL W F J T F. Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus [J]. 2011, 278(8): 1203-12.

KHATOON J, PRASAD K N, RAI R P, et al. Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer [J]. 2017, 74(3): 121-126.

BOQUET P, MICROBIOLOGY V R J T I. Intoxication strategy of Helicobacter pylori VacA toxin [J]. 2012, 20(4): 165-174.

ARACHCHI H S J, KALRA V, LAL B, et al. Prevalence of duodenal ulcer-promoting gene (dupA) of Helicobacter pylori in patients with duodenal ulcer in North Indian population [J]. 2007, 12(6): 591-700.

吴惠芳,朱亦璇,朱以军.幽门螺杆菌dupA基因与十二指肠溃疡关系的Meta分析[J].中国卫生检验杂志,2018(28):1989-92+95.

PATHOPHYSIOLOGY S M S J W J O G. Role of Toll-like receptors in Helicobacter pylori infection and immunity [J]. 2014, 5(3): 133-146.

NAGASHIMA H, IWATANI S, CRUZ M, et al. Toll-like Receptor 10 in Helicobacter pylori Infection [J]. 2015, 212(10): 1666-1676.

LIYA Z, HONG L, ZHIQIANG S, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment %J Chinese Medical Journal [J]. 2022.

赵霞,徐薇薇,刘益萌,等.中国大陆地区幽门螺杆菌对常用抗生素耐药性的临床分析[J].基础医学与临床,2022(42):1077-1082.

赵飞燕,崔立红.幽门螺杆菌治疗进展[J].胃肠病学和肝病学杂志,2022(31):492-497.

WU Y, DONG X Y, ZHOU X Z, et al. Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication [J]. Journal of digestive diseases, 2022, 23(8-9): 462-472.

CREMON C, BARBARO M R, VENTURA M, et al. Pre- and probiotic overview [J]. 2018, 43: 87-92.

阿热爱·巴合提,谭春明,李平兰.益生菌的分类及其多领域应用研究现状 [J].生物加工过程,2022(20):88-94.

ZHOU Y, LI T. Effects of Quadruple Therapy Combined with Probiotics on Helicobacter Pylori-Related Peptic Ulcer [J]. Computational and mathematical methods in medicine, 2022(2022): 1221190.

HE C, XIE Y, ZHU Y, et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial [J]. Frontiers in immunology, 2022(13): 1033063.

万慧颖,李超,李薇,等.中药抗幽门螺杆菌作用机制研究进展[J].中国实验方剂学杂志,2023,29(3):203-212.

胡婧楠,廖曼,田亚欣.清热解毒祛湿方经MyD88/NF-κB通路对幽门螺杆菌感染大鼠的抗炎作用实验研究 [J].四川中医,2023(41):83-87.

张思依,吕文亮,徐婧,等.基于NLRP3炎症小体通路探讨连朴饮对幽门螺杆菌感染大鼠胃黏膜损伤的保护机制[J].时珍国医国药,2023,34(1):81-84.

王猛,穆红.幽门螺杆菌致病机制与防治研究进展 [J].中华临床实验室管理电子杂志,2017,5(3):135-140.

邹全明.幽门螺杆菌疫苗[J].科技导报,2016(34):31-39.

LYU Q-J, PU Q-H, ZHONG X-F, et al. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials [J]. 2019, 2019: 9781212.

RAJ J R M, MICROBIOLOGY I K J C R I. Phages amid antimicrobial resistance [J]. 2019, 45(5-6): 701-11.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v6i7.13349